Stockscreener 앱 받기
5.01
2.72%
-0.14
시간 외 거래:
5.02
0.010
+0.20%
전일 마감가:
$5.15
열려 있는:
$5.1223
하루 거래량:
25,120
Relative Volume:
0.64
시가총액:
$215.56M
수익:
$4.71M
순이익/손실:
$-46.77M
주가수익비율:
-2.9836
EPS:
-1.6792
순현금흐름:
$-60.34M
1주 성능:
-1.76%
1개월 성능:
+4.38%
6개월 성능:
-37.14%
1년 성능:
-54.08%
1일 변동 폭
$5.01
$5.225
1주일 범위
$5.01
$5.39
52주 변동 폭
$4.345
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
NYXH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
5.01 | 221.59M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
535.00 | 191.90B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
207.11 | 59.36B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.00 | 39.13B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.58 | 38.05B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
44.12 | 33.62B | 27.43B | 1.27B | 1.01B | 1.5829 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-31 | 개시 | H.C. Wainwright | Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2022-04-21 | 개시 | Oppenheimer | Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Peer Perform |
| 2021-12-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-07-28 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Nyxoah Sa 주식(NYXH)의 최신 뉴스
Aug Sectors: Is Flanigans Enterprises Inc stock a falling knife or bargain buy2025 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(NYXH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NYXH: Rapid U.S. launch and strong clinical results position Genio for significant market growth - TradingView — Track All Markets
NYXH: Genio's innovative sleep apnea device drives rapid U.S. adoption and strong early sales - TradingView — Track All Markets
Oppenheimer Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $13 - 富途牛牛
Nyxoah’s First Full U.S. Sales Quarter Fuels Triple-Digit Revenue Growth in 2025 - TipRanks
Nyxoah (NASDAQ: NYXH) reports preliminary 2025 results and Q1 2026 view - Stock Titan
Stifel Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Stifel reiterates Buy rating on Nyxoah stock, maintains $12 price target - Investing.com Australia
Is Nyxoah SA stock a safe investment in uncertain markets2025 Growth vs Value & Verified Swing Trading Watchlist - Bộ Nội Vụ
Belgium-based Nyxoah’s net revenue expected to increase 348% in Q4 2025 - Medical Buyer
Nyxoah Shares Surge On Strong Q4 Preliminary Revenue - Nasdaq
Nyxoah Announces Preliminary Results for the Fourth Quarter - GlobeNewswire
Nyxoah SA's (EBR:NYXH) market cap rose €19m last week; retail investors who hold 44% profited and so did insiders - simplywall.st
Publication relating to transparency notification - GlobeNewswire
Aug Opening: Is Nyxoah SA stock a contrarian buyJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - Bộ Nội Vụ
Is Nyxoah SA stock a good choice for value investorsSeasonal Picks & what to check before ordering - Улправда
Is Nyxoah SA stock a contrarian buyMarket Risk Summary & Free Fast Gain Swing Trade Alerts - Улправда
How Nyxoah SA (5YI) stock benefits from digital adoptionPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - ulpravda.ru
Aug Intraday: Is Nyxoah SA stock a good choice for value investors2025 Technical Overview & Community Consensus Trade Alerts - Улправда
Why Nyxoah SA stock is recommended by analysts2025 Pullback Review & Safe Entry Momentum Stock Tips - Улправда
Nyxoah SA (NYXH) Stock Analysis: Exploring a Potential 125.84% Upside in the Healthcare Sector - DirectorsTalk Interviews
Nyxoah receives Medicare reimbursement increases for Genio - MSN
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
PRN_FinancialWrapper | PR NewswireNyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Star TribuneNyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Contrasting Azenta (NASDAQ:AZTA) and Nyxoah (NASDAQ:NYXH) - Defense World
Baird Maintains Nyxoah SA(NYXH.US) With Hold Rating, Cuts Target Price to $5.87 - 富途牛牛
Nyxoah to Participate in Upcoming Investor Conferences - Macau Business
Nyxoah SA (NYXH) Stock Analysis: Exploring a 145.53% Potential Upside in the Medical Tech Sector - DirectorsTalk Interviews
Nyxoah announces commercial launch of Genio system in the Netherlands - MSN
Nyxoah launches Genio therapy in Netherlands and closes first €22.5 million tranche of convertible notes - MSN
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - MSN
Nyxoah Announces Issuance of First Tranche of Convertible Bonds - The Manila Times
Is Nyxoah SA stock positioned for digital transformationQuarterly Trade Review & Consistent Return Investment Signals - Улправда
Nyxoah Launches Genio Therapy in Netherlands and Closes First €22.5 Million Tranche of Convertible Notes - TipRanks
Earnings Recap: Is Nyxoah SA stock a good choice for value investorsJuly 2025 Highlights & Target Return Focused Picks - Bộ Nội Vụ
Can Nyxoah SA stock deliver strong Q4 earningsQuarterly Growth Report & Smart Swing Trading Alerts - DonanımHaber
Is Nyxoah SA (5YI) stock undervalued historicallyJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
Sleep apnea device maker Nyxoah secures €22.5M to extend cash runway - Stock Titan
How Nyxoah SA stock performs in high volatility markets2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Nyxoah Launches New OSA Therapy | Patient-Centric Breakthrough - Precedence Research
Nyxoah Launches Genio Neurostimulator System in the Netherlands - marketscreener.com
New battery-free sleep apnea implant debuts in Dutch hospitals - Stock Titan
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands - GlobeNewswire
Nyxoah (NASDAQ:NYXH) Trading Down 2.9%Here's What Happened - MarketBeat
Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Here’s What Happened - Defense World
Nyxoah announces shareholding changes as Robert Taub surpasses 10% threshold - MSN
Critical Analysis: Nyxoah (NASDAQ:NYXH) & P3 Health Partners (NASDAQ:PIII) - Defense World
Nyxoah Announces Shareholding Changes as Robert Taub Surpasses 10% Threshold - TipRanks
How Nyxoah SA (5YI) stock compares with tech leadersWeekly Stock Analysis & Community Verified Trade Signals - Newser
Nyxoah Sa (NYXH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
1.19%
자본화:
|
볼륨(24시간):